Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05615012 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT05615012 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 76 participants.
The verdict
NCT05615012, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.
Interventions
- DRUG Metformin
- DRUG Methotrexate
- DRUG Rosuvastatin
- DIETARY_SUPPLEMENT Glucose
- DRUG BMS-986322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05615012
The ClinicalTrials.gov registry entry for NCT05615012 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT05615012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05615012 about?
NCT05615012 is a clinical study titled "A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants". The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.
What is the current status of trial NCT05615012?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2022-11-11. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT05615012?
The interventions under investigation include: Metformin (DRUG), Methotrexate (DRUG), Rosuvastatin (DRUG), Glucose (DIETARY_SUPPLEMENT), BMS-986322 (DRUG).
Who is sponsoring clinical trial NCT05615012?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.